LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Roivant Sciences Ltd

Cerrado

SectorSanidad

13.98 -0.71

Resumen

Variación precio

24h

Actual

Mínimo

13.84

Máximo

14.12

Métricas clave

By Trading Economics

Ingresos

-22M

-274M

Ventas

-5.4M

2.2M

BPA

-0.29

Margen de beneficios

-12,622.627

Empleados

750

EBITDA

-284K

-284M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+15.7% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.2B

8.8B

Apertura anterior

14.69

Cierre anterior

13.98

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

148 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2025, 22:41 UTC

Principales Movimientos del Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept 2025, 16:04 UTC

Principales Movimientos del Mercado

Upexi Shares Climb on Solana Gains

14 sept 2025, 23:48 UTC

Charlas de Mercado

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 sept 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 sept 2025, 23:38 UTC

Charlas de Mercado

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 sept 2025, 23:04 UTC

Charlas de Mercado

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 sept 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 20:09 UTC

Ganancias

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept 2025, 19:23 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:16 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:03 UTC

Charlas de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept 2025, 18:59 UTC

Charlas de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept 2025, 18:38 UTC

Charlas de Mercado
Ganancias

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept 2025, 18:33 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept 2025, 18:22 UTC

Charlas de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept 2025, 16:56 UTC

Charlas de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept 2025, 16:22 UTC

Ganancias

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

12 sept 2025, 16:11 UTC

Ganancias

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept 2025, 15:37 UTC

Charlas de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept 2025, 15:22 UTC

Charlas de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept 2025, 15:07 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

15.7% repunte

Estimación a 12 Meses

Media 16.29 USD  15.7%

Máximo 19 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

148 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat